ASCO 2020 and ISPOR 2020

Progression-Free Survival (PFS) is a widely used measure of effectiveness in patient outcomes research.  However, without access to sources that provide direct information about disease progression, researchers may employ proxy indicators of PFS, such as time to discontinuation (TTD) or time to next treatment (TTNT). In this video presentation, ConcertAI’s Chief Scientific Officer Mark S. Walker, PhD, dives into results from a poster presentation at ISPOR 2020 and abstract for ASCO 2020 that investigated the performance of proxy measures against directly-observed measures of PFS by using structured and unstructured information from electronic medical records (EMR)  in ConcertAI’s Definitive Oncology Real-World Database.